ALZpath @AlZpath

🧠 June is Alzheimer's & Brain Awareness Month. This month, we recognize the individuals, families, caregivers and communities impacted by Alzheimer's disease, along with those dedicated to advancing awareness, research, diagnosis, and care. #AlzheimersDisease #ENDALZ

🚨What if Alzheimer’s could be detected years - even decades - before symptoms begin? 🧠 That future is closer than most people realize. 🚀 On the latest episode of @ProgressPotent1 I sat down with Mike Banville, CEO of @AlZpath After decades scaling global businesses, Mike is now focused on one of healthcare’s biggest challenges: 👉Making early, accessible Alzheimer’s detection a reality. We explore: • How ALZpath’s pTau217 antibody is enabling blood tests that may rival PET scans and spinal taps; • Why earlier detection could reshape clinical trials, treatment timing, and patient outcomes; • The bigger shift toward precision medicine and proactive brain health; This isn’t just about diagnostics - it’s about changing when the fight against Alzheimer’s begins. ⚕️ #Alzheimers #BrainHealth #Biotech #EarlyDetection #PrecisionMedicine #HealthcareInnovation #Dementia #Neuroscience #Longevity @FINNPartners @FPIPR @SiemensHealth @Roche @RocheDiaUSA @BCILifeSciences @BeckmanDx

@Roche received CE Mark approval for the Elecsys pTau217 blood test, developed with @EliLillyandCo & powered by ADDF-funded @AlZpath’s pTau217 antibody. The approval marks another important step toward broader access to scalable Alzheimer’s diagnostics. reut.rs/4dBdopf

@adpdnet Excited to see the conference underway. Looking forward to a great week of science at #ADPD2026.

With @adpdnet 2026 underway in Copenhagen, research featuring ALZpath’s pTau217 antibody appears across 29 scientific presentations. Highlights from this week’s program below. 🔗 Read more: alzpath.bio/broad-ad-pd-20…

1 week until AD/PD™ 2026 🧠 The global Alzheimer’s disease and Parkinson’s disease community will gather in Copenhagen, March 17–21. Attending and want to connect? Reach out to Jacob Hunter at [email protected] to schedule a meeting.

We’re attending AD/PD 2026! ALZpath is excited to join the AD/PD™ 2026 Conference, March 17–21, in Copenhagen, Denmark. If you will be attending and would like to connect, please reach out to Jacob Hunter at [email protected] to schedule a meeting. #ADPD2026

🧠The words we use around brain health matter. ALZpath has joined the Initiative to Change the “D-Word,” committing to remove outdated, stigmatizing language around cognitive impairment. 🔗Learn more in the full press release: alzpath.bio/alzpath-commit…

We’re pleased to participate in the Global BioInnovation Forum today during @jpmorgan #JPM2026. Our CEO Michael Banville will join a session moderated by @Gil_Bashe on how blood-based diagnostics are reshaping Alzheimer’s detection. 🕝 2:30 PM PT 🔗 1businessworld.com/global-bioinno…

Bold move aims to scale blood-based diagnostics globally as demand for earlier, more accessible Alzheimer’s disease detection accelerates longevity.technology/news/new-deal-… #longevity #Alzheimers #AlzheimersTesting #BloodTest #EarlyDetection #Neurodegeneration #HealthTech #MedTech

Live at #CTAD25: the ALZpath #pTau217 antibody is accelerating biomarker, proteomic & longitudinal research across leading institutions. 🔗See the full list of posters & presentations: alzpath.bio/wp-content/upl…

📢#CTAD2025 is just two weeks away! As we gear up to connect with leaders advancing Alzheimer’s disease diagnosis and research, we’re excited to launch our redesigned web experience – live today🔗Explore: alzpath.bio Attending? Let’s connect: [email protected]

How reliable are blood-based pTau217 tests compared to PET or CSF? Studies show blood tests powered by the #pTau217 antibody perform comparably to CSF tests for detecting Alzheimer’s disease - a major step toward earlier, more accessible diagnosis. 🔗 alzpath.bio/faqs

ALZpath’s proprietary #pTau217 antibody has been named Diagnostics Innovation of the Year by the 2025 #BioTechBreakthroughAwards — recognizing its impact in advancing earlier, more accessible #AlzheimersDisease detection. 🔗Read more: alzpath.bio/alzpath-propri…

Pharma & biotech innovation is accelerating in 2025, from needle-free anaphylaxis rescue to AI-boosted newborn screening and blood-based Alzheimer’s diagnostics. The top 15 most innovative pharma & biotech companies of 2025, taken from Fast Company’s list, are redefining discovery, delivery and patient impact. 📊 Explore our infographic to see who’s leading and why: • ARS Pharma (@ars_pharma) • Bristol Myers Squibb (@bmsnews) • Eli Lilly (@EliLillyandCo) • Aurion Biotech (@AurionBiotech) • Iovance Biotherapeutics (@IovanceBio) • Adaptimmune (@Adaptimmune) • Verona Pharma (@VeronaPharma) • Pfizer (@pfizer) • ImmunityBio (@ImmunityBio) • Zevra Therapeutics (@zevratx) • ALZpath (@AlZpath) • GeneDX (@GeneDx) • 10x Genomics (@10xGenomics) • Protagonist Therapeutics (@ProtagonistTx) • Recursion (@RecursionPharma) 👉 Read more here: buff.ly/3akY1uy #Pharma #Biotech #Innovation #DrugDiscovery #ClinicalTrials #RareDisease #Oncology #Respiratory #Alzheimers #Genomics

In a new article from @PMLiVEcom, ALZpath Distinguished Scientific Advisor Dr. Henrik Zetterberg shares three pillars advancing #Alzheimers blood testing - sensitivity, accessibility, and education - powered by #biomarkers like #pTau217. 🔗Read now pmlive.com/intelligence/t…

We’re headed to #CTAD2025 in San Diego! ALZpath will join global leaders in Alzheimer's disease research & diagnostics to discuss advances in #pTau217 and blood-based biomarkers. Attending? Let’s connect - Reach out at [email protected] to schedule a meeting. @CTADconference

@AlamarBio is advancing Alzheimer’s disease research with the launch of the NULISAqpcr™ BD-pTau217 Assay, built on ALZpath’s pTau217 antibody. This launch broadens access to brain-specific blood-based biomarkers and marks another step forward in bringing innovative tools to AD.

AlamarBio @AlamarBio

8 months ago

🚀Just Launched: NULISAqpcr™ BD-pTau217 Assay! A game-changer in Alzheimer’s research—our new blood-based assay delivers unmatched sensitivity and CNS specificity for detecting brain-derived pTau217. Learn more: ow.ly/vnxg50X9ucE Read the release: ow.ly/5HjP50X9ucA

0 0 0 35 0

@US_FDA #diagnostics #AlzheimersDisease #FDA #Biomarker #pTau217 #ALZpath

The @US_FDA approved LEQEMBI® IQLIK™, a new at-home injectable that targets amyloid to help slow early #Alzheimers. Weekly at-home care removes infusion visits and improves access. #EarlyDetection is key to ensuring patients can benefit most. 📖time.com/7314266/alzhei…